Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Brunei Darussalam has been steadily growing in recent years.
Customer preferences: Patients suffering from rheumatic diseases in Brunei Darussalam are increasingly opting for Anti-Rheumatic Drugs as a treatment option. This is due to the effectiveness of these drugs in reducing inflammation and pain associated with rheumatoid arthritis and other rheumatic diseases. Additionally, the availability of a wide range of Anti-Rheumatic Drugs in Brunei Darussalam has made it easier for patients to choose a drug that suits their individual needs.
Trends in the market: One trend that has been observed in the Anti-Rheumatic Drugs market in Brunei Darussalam is the increasing preference for biologic drugs over traditional non-steroidal anti-inflammatory drugs (NSAIDs). Biologic drugs are more effective in treating rheumatoid arthritis and other autoimmune diseases, and have fewer side effects than NSAIDs. Another trend is the growing popularity of combination therapies, where two or more Anti-Rheumatic Drugs are used together to achieve better results. This trend is expected to continue in the coming years as more research is conducted on the effectiveness of combination therapies.
Local special circumstances: One of the unique factors that contribute to the growth of the Anti-Rheumatic Drugs market in Brunei Darussalam is the high prevalence of rheumatic diseases in the country. According to a study conducted by the Ministry of Health, rheumatoid arthritis is the most common autoimmune disease in Brunei Darussalam, affecting around 1.5% of the population. This high prevalence of rheumatic diseases has led to an increased demand for Anti-Rheumatic Drugs in the country.
Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Brunei Darussalam is also influenced by broader macroeconomic factors. The country has a high per capita income and a well-developed healthcare system, which allows patients to access a wide range of medical treatments, including Anti-Rheumatic Drugs. Additionally, the government of Brunei Darussalam has been investing in healthcare infrastructure and services, which has contributed to the growth of the Anti-Rheumatic Drugs market in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
